XL-protein and YEDA sign business collaboration agreement to commercialize PASylated interferon superagonist
FREISING, GERMANY & REHOVOT, ISRAEL, October 21, 2014 –
Yeda…
XL-protein announces publication of key scientific data on its PASylation® technology
FREISING, GERMANY, August 30, 2013 – XL-protein GmbH announced…
XL-protein and GENERIUM sign broad therapeutic license and collaboration agreement to develop PASylated therapeutics for the Russian Federation
Freising, Germany & Moscow, Russia, June 25, 2013
XL-protein…